Table of Contents
SECURITIES AND EXCHANGE COMMISSION
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
Laval, Québec
H7V 4A7
SIGNATURES: | ||||||||
NEUROCHEM ANNOUNCES PRIVATE PLACEMENT OF US$80 MILLION AGGREGATE PRINCIPAL AMOUNT OF 6% SENIOR CONVERTIBLE NOTES AND 5% SENIOR SUBORDINATED CONVERTIBLE NOTES. | ||||||||
EXHIBIT I |
Table of Contents
NEUROCHEM INC. | ||||
May 2, 2007 | ||||
By: | /s/ David Skinner | |||
David Skinner, Vice President, | ||||
General Counsel and Corporate Secretary | ||||
Table of Contents
275 Armand-Frappier Blvd
Laval, Quebec
H7V 4A7 Canada
Table of Contents
-2-
Table of Contents
![]() | Neurochem Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 |
Lise Hébert, Ph.D. | Tel: (450) 680-4572 | |
Vice President, Corporate Communications | lhebert@neurochem.com |
AGGREGATE PRINCIPAL AMOUNT OF 6% SENIOR CONVERTIBLE NOTES
AND 5% SENIOR SUBORDINATED CONVERTIBLE NOTES.
Table of Contents
2
Table of Contents
3
Table of Contents
Table of Contents
2
Table of Contents
3
Table of Contents
4
Table of Contents
5
Table of Contents
6
Table of Contents
7
Table of Contents
8
Table of Contents
9
Table of Contents
10
Table of Contents
11
Table of Contents
12
Table of Contents
13
Table of Contents
14
Table of Contents
15
Table of Contents
16
Table of Contents
275 Armand-Frappier Boulevard
Laval, Quebec H7V 4A7
Canada
Telephone: (450) 680-4500
Facsimile: (450) 680-4501
Attention: Chief Executive Officer
1501 McGill College Ave.
Montreal, Quebec H3A 3N9
Canada
Telephone: (514) 841-6400
Facsimile: (514) 841-6499
Attention: Richard D.Cherney & Neil Kravitz
919 Third Avenue
New York, New York 10022
Telephone: (212) 756-2000
Facsimile: (212) 593-5955
Attention: Eleazer N. Klein, Esq.
17
Table of Contents
18
Table of Contents
19
Table of Contents
COMPANY: NEUROCHEM INC. | ||||
By: | ||||
Name: | ||||
Title: |
Table of Contents
BUYERS: HUDSON BAY FUND LP | ||||
By: | ||||
Name: | ||||
Title: |
Table of Contents
BUYERS: HUDSON BAY OVERSEAS FUND LTD | ||||
By: | ||||
Name: | ||||
Title: |
Table of Contents
JP MORGAN OMNI SPC, Ltd. — BIOV1 SEGREGATED PORTFOLIO BY:Hudson Bay Capital Management LP, its investment advisor | ||||
Name: | ||||
Title: |
Table of Contents
Buyer’s Address | Buyer’s Representative’s | |||
Buyer | and Facsimile Number | Address and Facsimile Number | ||
Hudson Bay Fund, LP | 120 Broadway, 40th Floor New York, New York 10271 Attention: Yoav Roth May Lee Facsimile: 212-571-1279 Telephone: 212-571-12444 Residence: United States E-mail: yroth@hudsonbaycapital.com mlee@hudsonbaycapital.com | Schulte Roth & Zabel LLP 919 Third Avenue New York, New York 10022 Attn: Eleazer Klein, Esq. Facsimile: (212) 593-5955 Telephone: (212) 756-2000 | ||
Hudson Bay Overseas Fund, Ltd. | 120 Broadway, 40th Floor New York, New York 10271 Attention: Yoav Roth May Lee Facsimile: 212-571-1279 Telephone: 212-571-12444 E-mail: yroth@hudsonbaycapital.com mlee@hudsonbaycapital.com | Schulte Roth & Zabel LLP 919 Third Avenue New York, New York 10022 Attn: Eleazer Klein, Esq. Facsimile: (212) 593-5955 Telephone: (212) 756-2000 | ||
J.P. Morgan Omni SPC, Ltd. — BIOV1 Segregated Portfolio | 120 Broadway, 40th Floor New York, NY 10271 Email: investments@hudsonbaycapital.com | |||
Tang Capital Partners, LP | 4401 Eastgate Mall San Diego, CA 92121 | |||
Enable Growth Partners LP | One Ferry Building, Suite 255 San Francisco, CA 94104 Email: boneil@enablecapital.com | |||
Enable Opportunity Partners LP | One Ferry Building, Suite 255 San Francisco, CA 94104 |
Table of Contents
Buyer’s Address | Buyer’s Representative’s | |||||||||||
Buyer | and Facsimile Number | Address and Facsimile Number | ||||||||||
Radcliffe SPC, Ltd. for and on behalf of the Class A Segregated Portfolio | Radcliffe SPC, Ltd. for and on behalf of the Class A Segregated Portfolio c/o RG Capital Management, L.P. 3 Bala Plaza — East, Suite 501 Bala Cynwyd, PA 19004 Facsimile: (610) 617-0580 Telephone: (610) 617-5900 Email: chinkel@radcliffefunds.com gstahlecker@radcliffefunds.com ops@radcliffefunds.com | Drinker Biddle & Reath, LLP One Logan Square 18th & Cherry Streets Philadelphia, PA 19103 Attn: Stephen T. Burdumy Telephone: (215) 988-2880 Facsimile: (215) 988-2757 Email: Stephen.burdumy@dbr.com | ||||||||||
Capital Ventures International by: Heights Capital Management, Inc. its authorized agent | c/o Heights Capital Management 101 California Street, Suite 3250 San Francisco, CA 94111 Email: martin.kobinger@siq.com martin.hoe@siq.com Andrew.singer@siq.com | |||||||||||
Portside Growth and Opportunity Fund | c/o Ramius Capital Group, LLC 666 Third Avenue, 26th Floor New York, NY 10017 Email: jsmith@ramius.com tzanios@ramius.com OLittman@ramius.com nwu@ramius.com | |||||||||||
JGB Capital, L.P. | ||||||||||||
JGB Offshore Ltd. | ||||||||||||
Iroquois Capital, L.P. |
Table of Contents
OF REGISTRATION STATEMENT
100 University Avenue, 9th Floor
Toronto, Ontario
Canada M5J 2Y1
1
Table of Contents
Very truly yours, [ISSUER’S COUNSEL] | ||||
By: | ||||
2
Table of Contents
1
Table of Contents
Maximum Number of | ||||||||||||
Number of Shares | Shares to be Sold | Number of Shares | ||||||||||
Owned Prior to | Pursuant to this | Owned After | ||||||||||
Name of Selling Shareholder | Offering | Prospectus | Offering | |||||||||
Hudson Bay Fund LP (1) | 0 | |||||||||||
Hudson Bay Overseas Fund LTD (2) J.P. Morgan Omni SPC, Ltd. — BIOV1 Segregated Portfolio | ||||||||||||
Tang Capital Partners, LP | ||||||||||||
Enable Growth Partners LP | ||||||||||||
Enable Opportunity Partners LP Radcliffe SPC, Ltd. for and on behalf of the Class A Segregated Portfolio Capital Ventures Internationalby: Heights Capital Management, Inc.its authorized agent | ||||||||||||
Portside Growth and Opportunity Fund | ||||||||||||
JGB Capital, L.P. | ||||||||||||
JGB Capital Offshore Ltd. | ||||||||||||
Iroquois Capital, L.P. |
(1) | Sander Gerber, Yoav Roth and John Doscas share voting and investment power over these securities. Each of Sander Gerber, Yoav Roth and John Doscas disclaim beneficial ownership over the securities held by Hudson Bay Fund LP. The selling stockholder acquired the securities offered for its own account in the ordinary course of business, and at the time it acquired the securities, it had no agreements, plans or understandings, directly or indirectly to distribute the securities. | |
(2) | Sander Gerber, Yoav Roth and John Doscas share voting and investment power over these securities. Each of Sander Gerber, Yoav Roth and John Doscas disclaim beneficial ownership over the securities held by Hudson Bay Overseas Fund LTD. The selling stockholder acquired the securities offered for its own account in the ordinary course of business, and at the time it acquired the securities, it had no agreements, plans or understandings, directly or indirectly to distribute the securities. |
2
Table of Contents
• | on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale; | ||
• | in the over-the-counter market; | ||
• | in transactions otherwise than on these exchanges or systems or in the over-the-counter market; | ||
• | through the writing of options, whether such options are listed on an options exchange or otherwise; | ||
• | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; | ||
• | block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; | ||
• | purchases by a broker-dealer as principal and resale by the broker-dealer for its account; | ||
• | an exchange distribution in accordance with the rules of the applicable exchange; | ||
• | privately negotiated transactions; | ||
• | short sales; | ||
• | sales pursuant to Rule 144; |
3
Table of Contents
• | broker-dealers may agree with the selling securityholders to sell a specified number of such shares at a stipulated price per share; | ||
• | a combination of any such methods of sale; and | ||
• | any other method permitted pursuant to applicable law. |
4
Table of Contents
5
Table of Contents
Table of Contents
-2-
Table of Contents
-3-
Table of Contents
-4-
Table of Contents
-5-
Table of Contents
-6-
Table of Contents
-7-
Table of Contents
-8-
Table of Contents
-9-
Table of Contents
-10-
Table of Contents
-11-
Table of Contents
-12-
Table of Contents
-13-
Table of Contents
-14-
Table of Contents
-15-
Table of Contents
-16-
Table of Contents
-17-
Table of Contents
-18-
Table of Contents
-19-
Table of Contents
-20-
Table of Contents
-21-
Table of Contents
-22-
Table of Contents
-23-
Table of Contents
-24-
Table of Contents
-25-
Table of Contents
-26-
Table of Contents
-27-
Table of Contents
275 Armand-Frappier Boulevard
Quebec H7V 4A7
Canada
Telephone: (450) 680-4500
Facsimile: (450) 680-4501
Attention: David Skinner
1501 McGill College Ave.
Montreal, Quebec H3A 3N9
Canada
Telephone: (514) 841-6400
Facsimile: (514) 841-6499
Attention: Richard D. Cherney
-28-
Table of Contents
Montreal, Quebec H3A 3S8
Canada
Telephone: (514) 982-7888
Facsimile: (514) 982-7580
Attention: Mr. Yves Diallo
If to a Buyer, to its address and facsimile number set forth on the Schedule of Buyers, with copies to such Buyer’s representatives as set forth on the Schedule of Buyers, |
919 Third Avenue
New York, New York 10022
Telephone: (212) 756-2000
Facsimile: (212) 593-5955
Attention: Eleazer N. Klein, Esq.
or to such other address and/or facsimile number and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine containing the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively. |
-29-
Table of Contents
-30-
Table of Contents
-31-
Table of Contents
-32-
Table of Contents
COMPANY: NEUROCHEM INC. | ||||
By: | ||||
Name: | ||||
Title: | ||||
By: | ||||
Name: | ||||
Title: | ||||
Table of Contents
BUYERS: HUDSON BAY FUND LP | ||||
By: | ||||
Name: | ||||
Title: | ||||
Table of Contents
BUYERS: HUDSON BAY OVERSEAS FUND LTD | ||||
By: | ||||
Name: | ||||
Title: | ||||
Table of Contents
BUYERS: [OTHERS] | ||||
By: | ||||
Name: | ||||
Title: | ||||
Table of Contents
(1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | |||||||
Legal | ||||||||||||||
Aggregate | Aggregate | Representative’s | ||||||||||||
Principal | Principal | Number of | Number of | Address | ||||||||||
Address and | Amount of | Amount of | Series A | Series B | and Facsimile | |||||||||
Buyer | Facsimile Number | Senior Notes | Junior Notes | Warrant Shares | Warrant Shares | Purchase Price | Number | |||||||
Hudson Bay Fund, LP | 120 Broadway, 40th Floor | $4,300,000 | $4,300,000 | 84,779 | 136,818 | $8,600,000 | Schulte Roth & Zabel LLP | |||||||
New York, New York 10271 | 919 Third Avenue | |||||||||||||
Attention: Yoav Roth | New York, New York 10022 | |||||||||||||
May Lee | Attention: Eleazer Klein, Esq. | |||||||||||||
Facsimile: 212-571-1279 | Facsimile: (212) 593-5955 | |||||||||||||
Telephone: 212-571-12444 | Telephone: (212) 756-2376 | |||||||||||||
Residence: United States | ||||||||||||||
E-mail: yroth@hudsonbaycapital.com | ||||||||||||||
mlee@hudsonbaycapital.com | ||||||||||||||
Hudson Bay Overseas | 120 Broadway, 40th Floor | $5,700,000 | $5,700,000 | 112,382 | 181,364 | $11,400,000 | Schulte Roth & Zabel LLP | |||||||
Fund, Ltd. | New York, New York 10271 | 919 Third Avenue | ||||||||||||
Attention: Yoav Roth | New York, New York 10022 | |||||||||||||
May Lee | Attention: Eleazer Klein, Esq. | |||||||||||||
Facsimile: 212-571-1279 | Facsimile: (212) 593-5955 | |||||||||||||
Telephone: 212-571-12444 | Telephone: (212) 756-2376 | |||||||||||||
E-mail: yroth@hudsonbaycapital.com | ||||||||||||||
mlee@hudsonbaycapital.com | ||||||||||||||
Table of Contents
(1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | |||||||
Legal | ||||||||||||||
Aggregate | Aggregate | Representative’s | ||||||||||||
Principal | Principal | Number of | Number of | Address | ||||||||||
Address and | Amount of | Amount of | Series A | Series B | and Facsimile | |||||||||
Buyer | Facsimile Number | Senior Notes | Junior Notes | Warrant Shares | Warrant Shares | Purchase Price | Number | |||||||
J.P. Morgan Omni SPC, | 120 Broadway, 40th Floor | $10,000,000 | $10,000,000 | 197,161 | 318,182 | $20,000,000 | ||||||||
Ltd. — BIOV1 | New York, NY 10271 | |||||||||||||
Segregated Portfolio | Email: investments@hudsonbaycapital.com | |||||||||||||
Enable Growth Partners | One Ferry Building, Suite 255 | $3,400,000 | $3,400,000 | 67,035 | 108,182 | $6,800,000 | ||||||||
LP | San Francisco, CA 94104 | |||||||||||||
Email: boneil@enablecapital.com | ||||||||||||||
Enable Opportunity | One Ferry Building, Suite 255 | $600,000 | $600,000 | 11,830 | 19,091 | $1,200,000 | ||||||||
Partners LP | San Francisco, CA 94104 | |||||||||||||
Radcliffe SPC, Ltd. for | Radcliffe SPC, Ltd. for and on behalf | $3,250,000 | $3,250,000 | 64,077 | 103,409 | $6,500,000 | Drinker Biddle & Reath, LLP | |||||||
and on behalf of the | of the Class A Segregated Portfolio | One Logan Square | ||||||||||||
Class A Segregated | c/o RG Capital Management, L.P. | 18th & Cherry Streets | ||||||||||||
Portfolio | 3 Bala Plaza - East, Suite 501 | Philadelphia, PA 19103 | ||||||||||||
Bala Cynwyd, PA 19004 | Attn: Stephen T. Burdumy | |||||||||||||
Facsimile: (610) 617-0580 | Telephone: (215) 988-2880 | |||||||||||||
Telephone: (610) 617-5900 | Facsimile: (215) 988-2757 | |||||||||||||
Email: chinkel@radcliffefunds.com | Email: Stephen.burdumy@dbr.com | |||||||||||||
gstahlecker@radcliffefunds.com | ||||||||||||||
ops@radcliffefunds.com | ||||||||||||||
Capital Ventures | c/o Heights Capital Management | $3,250,000 | $3,250,000 | 64,077 | 103,409 | $6,500,000 | ||||||||
International | 101 California Street, Suite 3250 | |||||||||||||
by: Heights Capital | San Francisco, CA 94111 | |||||||||||||
Management, Inc. | Email: martin.kobinger@siq.com | |||||||||||||
its authorized agent | martin.hoe@siq.com | |||||||||||||
Andrew.singer@siq.com | ||||||||||||||
Portside Growth and | c/o Ramius Capital Group, LLC | $2,500,000 | $2,500,000 | 49,290 | 79,545 | $5,000,000 | ||||||||
Opportunity Fund | 666 Third Avenue, 26th Floor | |||||||||||||
New York, NY 10017 | ||||||||||||||
Email: jsmith@ramius.com | ||||||||||||||
tzanios@ramius.com | ||||||||||||||
OLittman@ramius.com | ||||||||||||||
nwu@ramius.com | �� | |||||||||||||
Tang Capital Partners, | 4401 Eastgate Mall | $4,000,000 | $4,000,000 | 78,864 | 127,273 | $8,000,000 | ||||||||
LP | San Diego, CA 92121 | |||||||||||||
JGB Capital, L.P. | $1,125,000 | $1,125,000 | 22,181 | 35,795 | $2,250,000 | |||||||||
JGB Capital Offshore | $375,000 | $375,000 | 7,394 | 11,932 | $750,000 | |||||||||
Ltd. | ||||||||||||||
Iroquois Capital, L.P. | $1,500,000 | $1,500,000 | 29,574 | 47,727 | $3,000,000 |
Table of Contents
Exhibit A | Form of Senior Notes | |
Exhibit B | Form of Junior Notes | |
Exhibit C | Form of Warrants | |
Exhibit D | Registration Rights Agreement | |
Exhibit E | Irrevocable Transfer Agent Instructions | |
Exhibit F-1 | Form of Outside Canadian Counsel Opinion | |
Exhibit F-2 | Form of Outside United States Counsel Opinion | |
Exhibit G | Form of Board Resolutions | |
Exhibit H | Form of Secretary’s Certificate | |
Exhibit I | Form of Officer’s Certificate | |
Exhibit J | Form of Lock-Up Agreement | |
Exhibit K | Form of Voting Agreement |
Schedule 3(a) | Subsidiaries | |
Schedule 3(e) | Consents | |
Schedule 3(l) | Absence of Certain Changes | |
Schedule 3(r) | Equity Capitalization | |
Schedule 3(q) | Transactions with Affiliates | |
Schedule 3(t) | Absence of Litigation | |
Schedule 3(z) | Subsidiary Rights | |
Schedule 3(aa) | Tax Status | |
Schedule 3(bb) | Internal Accounting | |
Schedule 3(cc) | Off Balance Sheet Arrangements |
Table of Contents
to the Securities Purchase Agreement
Name of Subsidiary | Jurisdiction of Incorporation/Constitution | |
Neurochem US LLC | USA | |
Neurochem Luxco I Sàrl | Luxembourg | |
Neurochem Luxco I SCS | Luxembourg | |
Neurochem Luxco II Sàrl | Luxembourg | |
Neurochem Holdings Limited | Switzerland | |
Neurochem (International) Limited | Switzerland |
Table of Contents
to the Securities Purchase Agreement
1. | The fulfillment of all of the conditions in the Toronto Stock Exchange’s conditional aproval letter with respect to the Company dated April 27, 2007. |
2. | Such consents, authorizations, filings or registrations as may be contemplated by the Transaction Documents. |
3. | The filing of a NASDAQ notification form: “Listing of Additional Shares” and supporting documentation. |
4. | The filing of a Form 45-106F1 —Report of Exempt Distributionwith the applicable Canadian securities regulatory authorities. |
5. | The filing of a Form 51-102F3 —Material Change Reportwith the applicable Canadian securities regulatory authorities as contemplated in Section 4(i). |
Table of Contents
to the Securities Purchase Agreement
1. | As described in the Company’s press release dated Feburary 21, 2007 entitled “Neurochem Reports Results for Fourth Quarter and Fiscal Year 2006” as filed on the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval website (“SEDAR”). |
2. | As described in the Company’s press release dated April 11, 2007 entitled “Neurochem’s Eprodisate (KIACTA™) PDUFA Date Extended by Three Months” as filed on SEDAR. |
3. | As described in the Company’s press release dated April 19, 2007 entitled “Neurochem Update on the North American Phase III Clinical Trial for tramiprosate (ALZHEMED™) for the Treatment of Alzheimer’s Disease” as filed on SEDAR. |
Table of Contents
to the Securities Purchase Agreement
Table of Contents
to the Securities Purchase Agreement
1. | With respect to clause (ii) of the sentence in Section 3(r) hereof which contains the reference to the present Schedule: The Company’s Amended and Restated Stock Option Plan, approved by the Company’s board of directors on February 21, 2007 and submitted for approval by the Company’s shareholders, the whole as disclosed as Schedule 1 to Schedule B to the Company’s Management Proxy Circular dated March 13, 2007 (the “Circular”). |
2. | With respect to clause (viii) of the sentence in Section 3(r) hereof which contains the reference to the present Schedule: The Company’s Deferred Share Unit Plans adopted effective January 1, 2007 and more fully described in the Circular. |
3. | With respect to clauses (ii), (iii), (v), (vi) and (vii) of the sentence in Section 3(r) hereof which contains the reference to the present Schedule: The Company’s 6% convertible senior notes due 2026 more fully described,inter alia, in the “Description of the Notes” section of the Short Form Base Shelf Prospectus of the Company dated February 9, 2007. |
4. | With respect to clauses (ii) and (v) of the sentence in Section 3(r) hereof which contains the reference to the present Schedule: The Company’s Equity Line of Credit more fully described,inter alia, in Note 11(f) to the Company’s consolidated financial statements for the years ended December 31, 2006, 2005 and 2004 and period from inception (June 17, 1993) to December 31, 2006 and in the following sections of the Short Form Base Shelf Prospectus of the Company dated February 9, 2007: “Our business”, “The Equity line of credit facility” and “Plan of distribution”. |
5. | With respect to clause (ii) of the sentence in Section 3(r) hereof which contains the reference to the present Schedule: The Performance Target Agreement (as that term is defined in the Circular) between Dr. Francesco Bellini and the Company, dated December 1, 2004, more fully described in the Circular. |
Table of Contents
to the Securities Purchase Agreement
Table of Contents
to the Securities Purchase Agreement
Table of Contents
to the Securities Purchase Agreement
Table of Contents
to the Securities Purchase Agreement
Table of Contents
to the Securities Purchase Agreement
1. | Operating lease obligations (including obligations under a sale-leaseback transaction) as described,inter alia, in Notes 5 and 15(a) to the Financial Statements. |
2. | The Company’s Equity Line of Credit more fully described,inter alia, in Note 11(f) to the Financial Statements and in the following sections of the Short Form Base Shelf Prospectus of the Company dated February 9, 2007: “Our business”, “The Equity line of credit facility” and “Plan of distribution”. |
3. | Obligations under letters of credit more fully described,inter alia, in Note 15(d) to the Financial Statements. |
Table of Contents
Number of Common Shares:
Date of Issuance: May , 2007 (“Issuance Date”)
Table of Contents
1 | For the Series A Warrants, insert number of shares equal to 25% of total number of Conversion Shares (as defined in the Securities Purchase Agreement) issuable upon conversion of the Senior Notes issued to the Holder on the Closing Date. For the Series B Warrants, insert the number of shares equal to 35% of the principal amount of Junior Notes issued to the Holder on the Closing Date divided by $11.00. |
-2-
Table of Contents
-3-
Table of Contents
B
-4-
Table of Contents
-5-
Table of Contents
-6-
Table of Contents
-7-
Table of Contents
-8-
Table of Contents
-9-
Table of Contents
-10-
Table of Contents
-11-
Table of Contents
-12-
Table of Contents
-13-
Table of Contents
-14-
Table of Contents
-15-
Table of Contents
(i) | the date actual payment of the amount due, in the case of any proceeding in the courts of New York or in the courts of any other jurisdiction that will give effect to such conversion being made on such date: or | ||
(ii) | the date on which the foreign court determines, in the case of any proceeding in the courts of any other jurisdiction (the date as of which such conversion is made pursuant to this Section 11(a)(ii) being hereinafter referred to as the “Judgment Conversion Date”). |
-16-
Table of Contents
-17-
Table of Contents
-18-
Table of Contents
-19-
Table of Contents
-20-
Table of Contents
-21-
Table of Contents
NEUROCHEM INC. | ||||
By: | ||||
Name: | ||||
Title: | ||||
Table of Contents
WARRANT TO PURCHASE COMMON SHARES
a “Cash Exercise” with respect to Warrant Shares; and/or | |||
a “Cashless Exercise” with respect to Warrant Shares (but only if applicable pursuant to Section 1(d) of the Warrant). |
Table of Contents
Name of Registered Holder | ||||
By: | ||||
Name: | ||||
Title: |
Table of Contents
NEUROCHEM INC. | ||||
By: | ||||
Name: | ||||
Title: |
Table of Contents
Issuance Date: , 2007 | Original Principal Amount: U.S. $[ ] | |
Note Certificate Number _____ |
Table of Contents
-2-
Table of Contents
-3-
Table of Contents
-4-
Table of Contents
-5-
Table of Contents
-6-
Table of Contents
-7-
Table of Contents
-8-
Table of Contents
1 | 4.99% for Radcliffe, Ramius and Heights |
-9-
Table of Contents
2 | Deleted from Radcliffe Note | |
-10-
Table of Contents
-11-
Table of Contents
3 | Insert date that is that is four months plus 1 day from Issuance Date. |
-12-
Table of Contents
-13-
Table of Contents
-14-
Table of Contents
-15-
Table of Contents
-16-
Table of Contents
-17-
Table of Contents
-18-
Table of Contents
-19-
Table of Contents
-20-
Table of Contents
-21-
Table of Contents
-22-
Table of Contents
-23-
Table of Contents
-24-
Table of Contents
-25-
Table of Contents
-26-
Table of Contents
-27-
Table of Contents
-28-
Table of Contents
-29-
Table of Contents
-30-
Table of Contents
-31-
Table of Contents
-32-
Table of Contents
-33-
Table of Contents
-34-
Table of Contents
-35-
Table of Contents
-36-
Table of Contents
-37-
Table of Contents
-38-
Table of Contents
-39-
Table of Contents
-40-
Table of Contents
-41-
Table of Contents
-42-
Table of Contents
-43-
Table of Contents
-44-
Table of Contents
Neurochem Inc. | ||||
By: | ||||
Name: | ||||
Title: | ||||
Table of Contents
CONVERSION NOTICE
Date of Conversion: | ||
Aggregate Conversion Amount to be converted: | ||
Conversion Price: | ||
Number of Common Shares to be issued: | ||
Issue to: | ||
Facsimile Number: | ||
Table of Contents
Authorization: | ||
By: | ||||
Title: | ||||
Dated: | ||||||
Account Number: | ||||||
(if electronic book entry transfer) |
Transaction Code Number: | ||||||
(if electronic book entry transfer) |
Table of Contents
Neurochem Inc. | ||||
By: | ||||
Name: | ||||
Title: |
Table of Contents
Issuance Date: _______ __, 2007 | Original Principal Amount: U.S. $[___] Note Certificate Number___ |
Table of Contents
-2-
Table of Contents
-3-
Table of Contents
-4-
Table of Contents
-5-
Table of Contents
-6-
Table of Contents
-7-
Table of Contents
-8-
Table of Contents
1 | 4.99% for Radcliffe, Ramius and Heights |
-9-
Table of Contents
2 | Deleted from Radcliffe Note | |
-10-
Table of Contents
3 | Insert date that is that is four months plus 1 day from Issuance Date. |
-11-
Table of Contents
-12-
Table of Contents
-13-
Table of Contents
-14-
Table of Contents
-15-
Table of Contents
-16-
Table of Contents
-17-
Table of Contents
-18-
Table of Contents
-19-
Table of Contents
-20-
Table of Contents
-21-
Table of Contents
-22-
Table of Contents
-23-
Table of Contents
-24-
Table of Contents
-25-
Table of Contents
-26-
Table of Contents
-27-
Table of Contents
-28-
Table of Contents
-29-
Table of Contents
-30-
Table of Contents
-31-
Table of Contents
-32-
Table of Contents
-33-
Table of Contents
-34-
Table of Contents
-35-
Table of Contents
-36-
Table of Contents
-37-
Table of Contents
-38-
Table of Contents
Neurochem Inc. | ||||
By: | ||||
Name: | ||||
Title: |
Table of Contents
CONVERSION NOTICE
Date of Conversion: | ||
Aggregate Conversion Amount to be converted: | ||
Conversion Price: | ||
Number of Common Shares to be issued: | ||
Issue to: | ||
Facsimile Number: | ||
Table of Contents
Authorization: | ||
By: | ||||
Title: |
Dated: | ||||||
Account Number: | ||||||
(if electronic book entry transfer) |
Transaction Code Number: | ||||||
(if electronic book entry transfer) |
Table of Contents
Neurochem Inc. | ||||
By: | ||||
Name: | ||||
Title: | ||||